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Abstract
The myelin sheath is a tightly packed multilayered membrane structure insulating selected axons in the central and the
peripheral nervous systems. Myelin is a biochemically unique membrane, containing a specific set of proteins. In this study,
we expressed and purified recombinant human myelin P2 protein and determined its crystal structure to a resolution of
1.85 A ˚. A fatty acid molecule, modeled as palmitate based on the electron density, was bound inside the barrel-shaped
protein. Solution studies using synchrotron radiation indicate that the crystal structure is similar to the structure of the
protein in solution. Docking experiments using the high-resolution crystal structure identified cholesterol, one of the most
abundant lipids in myelin, as a possible ligand for P2, a hypothesis that was proven by fluorescence spectroscopy. In
addition, electrostatic potential surface calculations supported a structural role for P2 inside the myelin membrane. The
potential membrane-binding properties of P2 and a peptide derived from its N terminus were studied. Our results provide
an enhanced view into the structure and function of the P2 protein from human myelin, which is able to bind both
monomeric lipids inside its cavity and membrane surfaces.
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Introduction
The myelin sheath is a multilayered membrane surrounding
selected axons in the vertebrate nervous system, formed by the
highly specialized plasma membrane of a myelinating glial cell.
Biochemically, myelin is formed of roughly 70–85% lipid, with a
high content of cholesterol [1], and only 15–30% of protein,
especially myelin-specific proteins. Peripheral myelin protein 2
(P2) constitutes up to 15% of total protein of peripheral nervous
system (PNS) myelin [2]. P2 is also present in small amounts in
central nervous system (CNS) myelin, being abundant in spinal
cord and brain stem myelin [3–5]. The amount of P2, however,
varies between different species, different regions of the nervous
system and from fiber to fiber [6]. P2 is localized at the major
dense line of myelin sheaths, and therefore, it is likely to play a
similar structural role in peripheral myelin as the myelin basic
protein (MBP) in both the CNS and PNS; the two proteins are,
however, genetically and structurally unrelated. As a structural
protein, P2 is thought to stabilize the myelin membranes. Our
recent neutron scattering experiments, indeed, have shown that
upon binding to lipid bilayers, P2 decreases the lipid dynamics [7].
By X-ray diffraction, it has been determined that myelin in
some species has wider major dense lines when there are large
amounts of P2 [8,9]. Human P2 is a basic cytosolic 131-amino-
acid 14.5-kDa protein, with a +10 net basic charge. Bovine
peripheral myelin P2 crystal structure was the first to be solved for
a full-length myelin protein [10,11]. Also the equine P2 crystal
structure was solved more recently [12]. The proteins were
purified from spinal cord in these studies.
Structurally, P2 belongs to the family of cytoplasmic fatty acid
binding proteins (FABPs) that has evolved by successive gene
duplications; the members of this family can solubilize and
transport fatty acids and retinoids in the cytoplasm [13–15].
Hence, P2 might have functions in myelin assembly and turnover.
However, the transport role of the FABPs has tissue dependent
differences in ligand specificity and binding affinity, and
consequently, in fatty acid metabolism [16].
P2 fragments are known to cause infammatory demyelination in
experimental allergic neuritis (EAN), an animal model of Guillain-
Barre ` syndrome (GBS) [17–19]. Also antibodies to P2 protein and
peptides have been found in GBS patients [20,21]. As P2 is not
known to be exposed at the cell surface, antibodies against it are
unlikely to initiate disease, and antibodies directed against myelin
proteins are likely to be directly involved in demyelination in only
a small proportion of GBS cases [22]. Chronic infammatory
demyelinating polyradiculoneuropathy CIDP, assumed to be the
chronic counterpart of acute GBS [18], is an acquired immune-
mediated infammatory disorder of the PNS, with a probable
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antigen most likely involved in the immune responses due to nerve
damage [23].
Traditionally, myelin proteins have been purified directly from
vertebrate nervous tissues. We use recombinant techniques to
produce myelin proteins, which enables the controlled production
of homogeneous samples with or without desired mutations. Here,
we purified recombinant human P2 in large scale and solved its
crystal structure. The structure was also characterized by small-
angle X-ray scattering (SAXS) and synchrotron radiation circular
dichroism spectroscopy (SRCD). Structure-based analyses of lipid
ligand binding were also carried out by computational and
fluorescence methods, and the membrane-binding properties were
studied using membrane mimics.
Materials and methods
Preparation of the human P2 expression vector
The cDNA of human P2 was purchased from RZPD (German
Resource Center for Genome Research). Primers for Gateway
cloning (Invitrogen) were from Oligomer. PCR reactions were
performed in two steps. The primers for the first PCR reaction
were 59AAAAAGCAGGCTCTGAGAATCTTTATTTTCAG-
GGCATGAGCAACAAATTCCG 39 and 59 AGAAAGCTG-
GGTTCAGACCTTCTCATAGATTCTG 39. In the second
PCR reaction, the forward primer 59 GGGGACAAGTTTGTA-
CAAAAAAGCAGGCT 39 and the reverse primer 59 GGGGAC-
CACTTTGTACAAGAAAGCTGGGT 39 were used to append
sites for homologous recombination at the end of the PCR
products. PCR was done using the Phusion High-Fidelity DNA
Polymerase (Finnzymes), according to the manufacturer’s instruc-
tions. PCR products were purified after both reactions using the
polyethylene glycol (PEG) protocol (Invitrogen, Gateway manual)
to remove small DNA fragments. The Gateway BP and LR
Clonase II Enzyme Mix kits (Invitrogen) were used for cloning,
according to the manufacturer’s instructions. Briefly, the PCR
product was recombined with the donor vector pDONR221
(Invitrogen) to create the entry clone. The products were
transformed into E. coli DH5a cells, and plasmids were purified
from 3-ml cultures, originating from single colonies, and
sequenced. The pTH27 plasmid, coding for an N-terminal His6-
tag [24], was used as the destination vector; recombination of the
destination vector with the entry clone yielded the expression
clone. After transformation into DH5a cells, colonies were picked,
and plasmid isolation and sequencing carried out. All cloning steps
were performed as described in the Gateway manual (Invitrogen),
but in downscaled reaction volumes (a total volume of 5.0 ml,
consisting of 3.0 ml of TE buffer pH 8.0, 0.5 ml of acceptor vector,
and 0.5 ml donor DNA, and 1 ml of Gateway BP or LR Clonase II
enzyme mix).
Recombinant protein expression
The P2 expression vector was transformed into E. coli
Rosetta(DE3) (Novagen). Overnight cultures were grown in
10 ml of LB with 100 mg/ml ampicillin and 34 g/ml chloram-
phenicol at +37uC. One liter of ZYM-5052 autoinduction medium
[25] was then inoculated with the overnight culture, and two
slightly different protocols for large-scale expression were used. For
the protein eventually used for crystallization, the cells were grown
at +20uC. After 16 h, 0.2 mM isopropyl-b-D-thiogalactoside and
additional 100 mg/ml ampicillin and 17 mg/ml chloramphenicol
were added. This addition was done to safeguard against loss of
lactose and antibiotics during the prolonged culture. The cells
were harvested after 36 h by centrifugation and stored at 270uC.
For the other batches of P2, the cells were grown first for 4 h at
+37uC and thereafter for 48 h at +18uC before harvesting.
Protein purification
20 ml of lysis buffer (50 mM Na phosphate pH 8.0, 300 mM
NaCl, 10 mM imidazole) and one Complete Mini EDTA-free
protease inhibitor tablet (Roche) were added per g of cells. The
suspension was mixed at +4uC and vortexed. Cells were disrupted
by sonication, and cell debris was removed by centrifugation at
20000 g for 45 min at +4uC. The supernatant was applied onto
Ni-NTA matrix (Qiagen) equilibrated with the lysis buffer. The
matrix was washed with 50 mM Na-phosphate pH 8.0, 300 mM
NaCl, 20 mM imidazole, and elution of His-P2 was done using
50 mM Na-Phosphate pH 8.0, 300 mM NaCl, 250 mM imidaz-
ole, following the absorbance at 280 nm.
The fractions were checked on SDS-PAGE gel and pooled. The
concentration was measured at 280 nm, and recombinant TEV
protease [26] was added at an approximate molar ratio of 1:30 to
His-P2. Cleavage was carried out for 24 h at +4uC, the sample was
concentrated in an Amicon Ultra-15 3K centrifugal filter device
(Millipore), and imidazole was removed using a PD-10 column
(GE Healthcare); this allowed for the removal of uncleaved His-
tagged protein by another passage through Ni-NTA in the case of
incomplete cleavage. The completeness of the cleavage was
analyzed on SDS-PAGE. The final purification step was done
by gel filtration on a Superdex 75 16/60 (GE Healthcare) column
in 20 mM HEPES pH 7.5, 50 mM NaCl, 10% glycerol.
For one batch, TEV cleavage was not carried out; rather, the
protein was dialyzed to remove excess imidazole. The His-tagged
protein was used only for three experiments: for a comparison of
tagged and non-tagged protein by SRCD, and the fluorescence
assays of DPC interaction (alongside with the non-tagged protein)
and cholesterol binding.
Synchrotron radiation circular dichroism spectroscopy
SRCD spectra for untagged P2 were collected on beamline
CD1 of the ASTRID storage ring at the University of A ˚rhus,
Denmark. P2 was dialyzed into 20 mM sodium phosphate
(pH 7.4). All sample and baseline spectra were collected in quartz
cells 3 times over the wavelengths 280 to 170 nm. The data were
processed using CDtool [27] and analyzed for secondary structure
using Dichroweb [28].
SRCD measurements were also performed at the BESSY
beamline 3m-NIM-C in a similar manner, essentially as previously
described [29]. In this case, the samples included His-tagged and
untagged P2, as well as a peptide from the N terminus of human
P2. The P2 samples were measured both in solution and as a dried
film, and the peptide in the presence and absence of different
membrane-mimicking compounds. The solution samples were
measured at concentrations between 0.6–1 mg/ml, in a quartz
cuvette of 100 mm pathlength. For measuring dry-phase SRCD
data, the optimal condition was found to be a protein
concentration between 0.5–1 mg/ml; one ml of this solution was
pipetted into the centre of a calcium fluoride circular cuvette. The
drop was allowed to evaporate standing still in the flow cabinet (a
few minutes), after which the cuvette was further incubated under
vacuum at +37uC for a few minutes. The cuvette was then inserted
into the sample holder; the circular cuvette was always in the same
orientation with respect to the incoming beam. For measuring the
dry phase spectra, the sample chamber was extensively flushed
with nitrogen gas, to remove traces of oxygen that otherwise
caused high absorbance at 165 nm. Data processing was carried
out using a local SRCD extension of IgorPro (Wavemetrics)
available at BESSY.
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was used to obtain a melting curve for P2. Briefly, the CD signal
was followed at 218 nm as a function of temperature (+20 to
+95uC, slope +1uC/min) in a Jasco J-715 Spectropolarimeter. The
protein concentration was 0.12 mg/ml and a 1-mm quartz cuvette
was used.
Small-angle X-ray scattering
For SAXS, P2 was dialyzed into a buffer containing 50 mM
HEPES (pH 7.5), 150 mM NaCl, and 10% glycerol. SAXS data
were measured at concentrations up to 4 mg/ml on the X33
synchrotron radiation beamline at EMBL-Hamburg, DESY. Data
processing and analysis were carried out using programs of the
ATSAS package [30], essentially as previously described [29].
Fluorescence titration of peptide-detergent interactions
A peptide from the N-terminus of P2 (residues 1–10,
SNKFLGTWKL, purchased from SBS Genetech, China) was
identified as a putative membrane binding site using Amphipaseek
[31]. Since the peptide contains a Trp residue, intrinsic
fluorescence spectroscopy was used to study its binding to
dodecylphosphocholine (DPC) micelles. The assay was performed
at +30uC using the Tecan Infinite M200 apparatus, in 96-well
plates. The peptide (10 mg/ml) was incubated at different
concentrations of DPC in 10 mM KPO4 buffer (pH 7), and
excitation was done at 295 nm. Emission spectra were measured
from 320 to 400 nm. Similarly, the recombinant human P2
protein, with and without His-tag, was analysed, at a concentra-
tion of 30 mg/ml.
Crystallization, data collection, structure determination
and refinement
The untagged protein was concentrated to 15 mg/ml and
crystallized at +4uC using a mother liquor containing 280 mM Na
phosphate, 100 mM Tris –HCl (pH 8.5), and 37% PEG4000.
Prior to data collection, a crystal was flash-frozen in liquid
nitrogen. Data were collected remotely using mxCUBE, at the
ID14-1 beamline of ESRF Grenoble. The data were processed
and scaled using XDS [32] and XDSi [33]. The data processing
statistics are shown in Table 1. The structure was solved by
molecular replacement using Phaser software [34] and the equine
P2 structure (PDB entry 1YIV, [12]); the crystal form had one
monomer per asymmetric unit. The structure was refined using
Refmac5 [35] and phenix.refine [36] and built and analyzed with
Coot [37]. The coordinates and structure factors were deposited at
the Protein Data Bank with the accession code 2WUT. Images
describing structural information were made with PyMol (www.
pymol.org) and CCP4mg [38].
Computational docking of lipids inside human P2
For docking simulations of cholesterol and palmitate with P2,
the crystal structure of human P2, after the removal of the fatty
acid ligand and water molecules, was used. The cholesterol
molecule was constructed using the PRODRG server [39], and
the partial charges generated by PRODRG were used after
checking. The partial charge of palmitate was added with the
VegaZZ server (http://nova.colombo58.unimi.it/vegawe.htm)
[40]. The docking simulations were performed both with the
AutoDock4 [41] and AutoDock Vina [42] packages, with the aid
of the AutoDockTools interface. All the active torsions of the
ligands were allowed to rotate freely during conformational
sampling. The grid maps were centred on the binding pocket of
the protein, with a box size of 29.25616.5621 A ˚. For the
AutoDock4 calculations, the Lamarckian genetic algorithm [43]
was used, performing 100 runs with 150 individuals in the
population, 27000 generations and 5?10
6 energy evaluations. A
cluster analysis was performed and the ligand conformation with
the lowest binding energy lay also in the more populated cluster.
This conformation corresponded to one of those found by
AutoDock Vina and was chosen for further analysis. Structural
analysis of the binding modes was made using PyMol, Swiss-
PdbViewer [44] and VMD [45]. Swiss-PdbViewer was also used
to calculate electrostatic potentials (EP) with the Poisson-
Boltzmann method.
Tryptophan fluorescence analysis of cholesterol binding
to P2
Absorbance and fluorescence measurements were done with a
Jasco UV-VIS 7850 spectrophotometer and a LS-50 Perkin Elmer
spectrofluorimeter, respectively.
The fluorescence spectra of the His-tagged P2 protein, 9.4 mM,
in HEPES buffer plus 150 mM NaCl pH 7.5, excited at 280 nm,
were recorded as a function of time, in the presence of 10 mM
cholesterol. Cholesterol was dissolved in ethanol, and the final
concentration of ethanol in the solution was 1% (v/v).
Results and Discussion
P2 is a peripheral membrane protein of the myelin sheath, and
our aim is to combine structural and functional information
obtained using the human recombinant P2 protein to elucidate the
structure-function relationships in this abundant myelin compo-
nent. This is an important step towards a more complete
understanding of the roles myelin proteins [46] play in the
formation and integrity of the myelin sheath, a compact
membrane structure crucial to the correct functioning of the
vertebrate nervous system.
Table 1. Crystallographic data collection and structure
refinement.
Data collection
Space group P41212
Unit cell dimensions (A ˚) a=66.3, b=66.3, c=101.2
Resolution (A ˚) 20-1.85 (1.90-1.85)
Rmerge (%) 6.0 (64.0)
,I/sI. 24.2 (2.3)
Completeness (%) 98.5 (87.8)
Redundancy 6.6 (4.7)
Refinement
Rcryst/Rfree (%) 16.6/20.9
RMS Deviations from ideal values
Bond lengths (A ˚) 0.007
Bond angles (u) 1.0
Average B factor/Wilson B (A ˚2) 28.9/23.8
Ramachandran plot (%)
Preferred regions 99.1
Allowed regions 0.9
Outliers 0
The values in parentheses correspond to the high-resolution shell.
doi:10.1371/journal.pone.0010300.t001
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From 1 l of autoinduced culture of Rosetta(DE3) cells, 100 mg
of pure human P2 were routinely obtained (Figure S1). The
importance of cell line selection was highlighted by the fact that
using the BL21(DE3) strain, practically no protein could be
obtained (data not shown). The sequence of human P2 contains a
number of rare codons for E. coli, including a total of 7 rare codons
for Arg, explaining the crucial need for a modified expression
strain. The protein had an apparent molecular weight of 15 kDa,
indicating monomeric structure, and it was highly soluble in
aqueous buffers. Tryptic peptide mapping by mass spectrometry of
a gel band showed that the purified fractions indeed contained
human myelin P2 protein (data not shown). Thus, a working large-
scale expression and purification system for recombinant human
PNS P2 myelin protein was accomplished. This system can be
used also in the future for further in-depth studies on P2 structure
and function, e.g. by site-directed mutagenesis coupled to structure-
function assays.
Conformational analysis by SRCD
The melting point of recombinant human P2 was determined to
be +62uC (data not shown), indicating a stable folding of the
recombinant protein. SRCD experiments were performed to
analyze the folding of human recombinant P2 in solution. The
SRCD spectrum of human recombinant P2 (Figure 1A) is
consistent with a protein that has a high b-sheet structure content,
having negative minima at 216 and 179 nm and a large positive
maximum at 198 nm.
The secondary structure content of P2 was analyzed at the
DichroWeb server [28]. As expected, the deconvolution indicated
a large fraction of beta structure, but different algorithms gave
significantly differing solutions. A typical solution with a good fit
indicated 17% a-helix, 48% b-sheet, and 35% other structures.
The accurate analysis of high-beta folds is a commonly known
caveat of CD spectrum deconvolution algorithms. The results do
show that recombinant human P2 is folded, as expected, into a
mainly b-sheet structure.
Dichrocalc [47] was used to calculate theoretical CD spectra
from the experimental atomic coordinates. The SRCD spectrum
of human recombinant P2 was then compared with the back-
calculated spectrum (Figure 1A). While the overall peak positions
agree quite well, the shape of the spectrum is rather different,
possibly pointing towards a specific signature of the beta barrel
fold of P2, or indicating flaws in the calculation algorithm.
T h eH i s - t a g g e da n dc l e a v e dP 2w e r ea l s oc o m p a r e du s i n gS R C D .
The results show that the His-tagged P2 is folded identically to
untagged P2 (data not shown); thus, His-P2 was also used for some of
the functional experiments on lipid binding (see below).
SRCD was also used to study P2 in the dry phase, i.e. as a film
dried onto the surface of the CaF2 cuvette. Such measurements on
other proteins were recently reported and found to correlate
reasonably well with solution data [48]. In the case of P2, the
spectra are nearly identical in the region available for solution
measurements (Figure 1B), indicating the protein retains its native
fold upon the drying procedure. This result further suggests the
method could have wider applicability for studying protein
conformation at very low vacuum UV (VUV) wavelengths, down
to 130 nm. The VUV region of the dried P2 protein shows a
strong maximum at 165 nm and minima at 150 and 170 nm.
Crystal structure
The crystal structures of myelin P2 protein from Bos taurus
(1PMP, 2.7 A ˚) and Equus caballus (1YIV, 2.1 A ˚) were previously
known [11,12]. Here, the structure of human recombinant P2 was
solved using molecular replacement at 1.85-A ˚ resolution (Table 1,
Figure 2A). The similarity to the bovine and equine P2 structures
is shown by the rms deviations of Ca positions of 0.60 and 0.68 A ˚,
respectively. The SAXS data further confirm that P2 is
monomeric in solution, and its shape in solution is highly similar
to that seen in the crystal structure (Figure 3, Table 2).
The mammalian FABP family includes nine tissue-specific
homologues sharing 20–70% amino acid sequence identity [13].
Based on their amino acid sequences, FABPs can be grouped into
three groups, which differ in their lipid binding characteristics.
The human myelin P2 protein shares the highest amino acid
sequence similarities with adipocyte, heart, brain, epidermal, and
testis FABP. This group of FABPs can bind fatty acids, retinoids
and eicosanoids [13,49].
Figure 1. SRCD analysis of human P2 conformation. A. SRCD data for human P2. The SRCD spectrum (thick line) was measured from P2 at
ASTRID, A ˚rhus. The thin line corresponds to the calculated spectrum based on the human P2 coordinates and the Dichrocalc algorithm. B.
Comparison of the SRCD spectra of P2 in solution (red) and as a dried film (black). The amount of protein, as evidenced by the measured absorbance
at 190 nm, between the two samples differs by less than 1%. The spectra were collected at the SRCD beamline at BESSY, which has a much lower flux
than the CD1 beamline of ASTRID.
doi:10.1371/journal.pone.0010300.g001
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other FABP members: 10 anti-parallel b-strands (referred to as
strands A–J in the discussion below), forming two nearly
orthogonal b-sheets that form an elliptical twisted b-barrel
[50,51]. The first two strands are linked together by two a-helices,
which close the barrel from one end. In FABPs, the fatty acid is
bound inside the barrel carboxyl head first [52]; while the
hydrophobic contacts are around the cavity entrance, hydrophilic
contacts are deep in the binding pocket (Figure 4A). The ligand
binding cavity extends from the helix-turn-helix motif, which
functions as a portal region for fatty acids. It is assumed that a
conformational change of the portal region occurs during fatty
acid binding or release [53]. The portal region may bind to
membranes, and this binding could catalyze a conformational
change. Some FABPs are cytosolic, only transferring fatty acids in
the cytosol, but P2 is an extrinsic membrane protein between
myelin membranes and possibly able to transfer fatty acids via a
direct interaction with membranes.
In the human P2 crystal structure, a palmitate molecule, well-
defined in the electron density (Figure 2B,4A), was modeled into
the lipid-binding cavity in a bent conformation, superimposing the
position and orientation of oleate in the bovine P2 structure [11].
The electron density of the bound ligand clearly indicated the
presence of a carboxyl group and a long aliphatic tail, very well
fitting a 16-carbon chain. Since no lipid ligands were added to the
sample at any stage of purification, the ligand must come from the
E. coli cells used for protein expression; palmitate being the most
abundant fatty acid in E. coli [54] also makes it a likely ligand for
recombinant P2. The carboxyl group of the ligand points inside
the barrel, closely interacting by means of H-bonds and salt
bridges with the side chains of Arg126, Arg106, and Tyr128, the
three residues totally buried into the inner cavity of the barrel that
are important for the binding of fatty acids and retinoids in the
FABP family [51,55]; these residues provide an overall basic
feature to the binding site surface.
A comparison between the three currently available crystal
structures for P2 indicates a conformational change at the mouth
of the lipid-binding cavity, involving Phe57, which lies in a loop
between b-strands C and D (Figure 4B). In human P2 and one
chain of the bovine P2 structure, it is closed on top of the cavity,
while in equine P2 and the remaining chains in the bovine P2
crystal, it is in an open conformation. A role for this residue in the
opening of the cavity and lipid binding has also been suggested
before [10,56]; it seems to be important for the formation of a
fatty-acid – FABP complex, and its mutation results in a loss of
fatty acid binding. The closed position of Phe57 in human P2
allows it to become in contact with the ligand present in the
binding pocket.
The presence of several well-ordered water molecules
(Figure 4C) inside the P2 cavity indicates that also larger, at least
partly more hydrophilic, ligands could be accommodated in this
space. A conserved structural water molecule in the FABP family
has also been reported; P2 was not analyzed in that study [57].
This water is located in a pocket close to the protein external
surface, in a wedge formed by the loop between b-strands D and
E. From the human P2 structure, it is evident that this water
molecule is also present, being H-bonded to the backbone NH
group of Val84 and the carbonyl oxygens of Lys65 and Gln68
Figure 3. The solution structure of human P2 as analyzed by SAXS. A. The small-angle X-ray scattering curve of human P2, at 4.4 mg/ml. The
dots represent the raw data and the curve the fit of the ab initio model to the raw data. B. Distance distribution for P2, as calculated by GNOM [65]. C.
Superposition of the ab initio SAXS solution structure model (green) and high-resolution crystal structure (magenta) of human P2. The solution
structure model was built by DAMMIN [66] and DAMAVER [67].
doi:10.1371/journal.pone.0010300.g003
Figure 2. Crystal structure of human P2. A. Overall structure of
human myelin protein P2. The bound fatty acid is shown as a solvent-
accessible surface. The N and C termini point downwards, and the
helical domain is at the top. B. Electron density of the bound fatty acid
molecule, which was modeled as a palmitic acid. The map is the final
2Fo-Fc map, contoured at 1 sigma.
doi:10.1371/journal.pone.0010300.g002
Human Myelin Protein P2
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molecule could stabilize the bD-bE loop [57]. Interestingly, main-
chain hydrogen bonds are lacking between bD and bE; therefore,
a more important structural role could be hypothesized for this
water molecule, which could help to keep together the walls of P2
across this structural gap.
The main autoimmune epitope of P2 locates at residues 58–73
[58], and a peptide corresponding to this region has been been
used extensively to induce and study the animal model of GBS,
EAN. The minimal T cell epitope of P2 includes a subset of this
region, residues 61–70 [59]. In EAN, a 16-mer of the P2(58–73)
peptide has also been used for treatment and vaccination [60]. At
the structural level (Figure 4D), the epitope localizes to a b-strand-
turn-b-strand unit, on the side opposite to the helical domain. In
fact, these are the strands bD and bE, between which no main-
chain hydrogen bonds exist. In addition, the epitope recognized by
GBS patients in a recent study [20] comprises residues 14–25,
which locates at the helical subdomain.
Potential membrane binding sites
The EP surface of the highly basic human P2 shows two large
opposite highly positive regions separated by an almost neutral rim
(Figure 5A). This charge distribution is shared by all the known P2
protein structures, and therefore, could be important for the
interaction of P2 with two apposing membrane leaflets of myelin.
This suggests a structural ‘‘glue’’ role for P2, analogous to that of
MBP in the CNS. Supporting this hypothesis, all the cytosolic
FABPs show a relatively featureless neutral, or slightly negative,
EP surface (data not shown), in spite of the overall structural
features they have in common with P2 proteins.
As another means of identifying membrane-binding segments,
we used sequence analysis in Amphipaseek [31]. The region
highlighted by the algorithm contains the N-terminus of P2,
Figure 4. Details from the P2 crystal structure. A. The contacts of the fatty acid molecule and P2, as a stereo view. Note that all hydrophilic
contacts are deep in the binding pocket, while the hydrophobic contacts are around the cavity entrance. The helical domain is highlighted in blue. B.
Comparison of Phe57 in the available P2 protein structures (human, green; bovine chain B, blue; equine, yellow). Via a rotation of the side chain, more
space can be made for larger ligands. C. In addition to the fatty acid (green/red), the P2 cavity is also filled by water (orange), indicating the possibility
of fitting larger and chemically variant ligands. Most of these water molecules are hydrogen bonded to the inner walls of the cavity. D. Mapping of
potential disease-linked epitopes onto human P2. The EAN epitope (residues 58–73) is highlighted in orange, and the epitope recognized by GBS
patients (residues 14–25) in blue.
doi:10.1371/journal.pone.0010300.g004
Table 2. Results from SAXS.
Rg (nm) Dmax (nm) Volume (nm
3) MW (kDa)*
P2 (SAXS) 1.54 4.5 22.9 11.3
P2 (crystal)** 1.53 4.7 21.1 16.1
*calculated based on a comparison with a calmodulin (17 kDa) model, which
has a volume of 34.3 nm
3.
**calculated from the atomic coordinates of the crystal structure using CRYSOL
[65].
doi:10.1371/journal.pone.0010300.t002
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charged surface areas discussed above. In the crystal structure
(Figure S2), this segment is bound to the protein surface, forming a
short 1-turn 310-helix, a structural feature strongly conserved in
the group of FABSs highly similar to P2, and an extended
fragment. The Trp residue is actually anchored under the C-
terminus of the protein. A part of the interaction is also formed by
the Met encoded by the start codon, which should be absent in the
native protein. Thus, the conformation of the very N terminus is
slightly different between the native bovine/equine and recombi-
nant human proteins. We synthesized a peptide corresponding to
this putative membrane binding region and studied its conforma-
tion upon binding to membrane mimics, such as DPC micelles,
using SRCD (Figure 5B). While the peptide had no significant
secondary structure in phosphate buffer, it showed strong helical
character in all the tested membrane-mimicking conditions,
including 0.5% DPC, 0.5% SDS, 0.5% DMAO, and 30% TFE.
Thus, at least outside the context of the full-length P2 protein, this
N-terminal sequence has a tendency to associate with membrane
mimics.
The interaction with DPC was also probed by fluorescence
spectroscopy, using the intrinsic signal from the Trp residue within
the peptide (Figure 5C). The results indicate that the environment
of the Trp residue in the peptide changes upon increasing
concentrations of DPC micelles. The difference peak is centered at
337 nm, and reaches a plateau at 0.5% DPC. These results
indicate direct binding of the peptide to DPC micelles. Using full-
length P2, both His-tagged and untagged, a fluorescence signal
was also induced by DPC in a concentration-dependent manner
(Figure 5D,S3). However, whether this is a result of the N-terminal
segment binding to DPC micelles, of the binding of monomeric
DPC inside P2, or both, remains a subject for future studies.
Figure 5. Possible membrane binding regions. A. Electrostatic potential of human P2; the view is the same as in Figure 2A. Note the positively
charged faces at the top and bottom. For the electrostatic potential map, shown as a mesh, cutoffs of 22.3 kbT/e (red) and +2.3 kbT/e (blue) were
used. The protein is visualized with its solvent-accessible surface, onto which the EP is mapped. B. SRCD analysis of the conformation of the N-
terminal peptide from P2 in the presence of different membrane-mimicking compounds. Black, buffer; green, 0.5% DPC; blue, 0.5% SDS; red, 30% TFE;
white, 0.5% DMAO. C. Titration of the P2 N-terminal peptide with DPC, followed by intrinsic Trp fluorescence. The DPC concentrations were 0.1
(black), 0.2 (red), 0.5 (blue), 1 (green), and 2 (magenta) %. Difference spectra are shown, i.e. the emission spectrum in the absence of DPC has been
subtracted. D. Titration of P2 with DPC, followed by intrinsic Trp fluorescence. Colouring of the difference spectra as in C. The titration of His-P2 is
shown in Figure S3.
doi:10.1371/journal.pone.0010300.g005
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simulations and fluorescence spectroscopy
measurements
The crystal structure of human P2 was used as a starting point
for lipid docking simulations, in order to investigate if the lipid
constituents of myelin could be bound by P2. While it has been
postulated that most of the major lipids found in myelin are much
larger than the binding pocket in P2 [12], this is not true for
cholesterol, which takes up a volume of 376 A ˚ 3 in its fully
extended conformation with all hydrogen atoms added. The
volume of the P2 binding pocket is 976.4 A ˚ 3 (as calculated by
CASTp [61]). In addition, also some other phospholipids, such as
dimyristoyl phosphatidyl ethanolamine (DMPE) could fit into the
P2 binding pocket (the volume of a bent conformation, as obtained
by preliminary docking measurements, has a volume of 649 A ˚ 3).
However, the best candidate was cholesterol, one of the most
abundant lipids in myelin, which has a polar head that fits very
well to the electrostatic characteristics of the binding site.
The docking simulations, both with AutoDock4 and AutoDock
Vina, converged to a structure that shows the ligand inside the
binding cavity in the same position as the crystallographically
detected ligand palmitate. The cholesterol molecule has its polar
region oriented towards the conserved Arg106-Arg126-Tyr128
(RRY) binding site (Figure 6A), forming a H-bond with Arg106.
For comparison and validation of the docking algorithms, docking
simulations were performed also with palmitate. The results show
that the ligand position and conformation are the same as in the
crystal structure, with exactly the same kind of interaction with the
RRY residues (Figure 6A, inset). The docking experiments
indicated cholesterol as a candidate for binding, with an affinity
computed of the same order of magnitude as palmitate, as
suggested by the respective estimated values for the free energy of
binding (data not shown).
Recently, it has been observed that the beta-barrel Niemann-
Pick Type C2 protein (NPC2), which plays a role in late
endosomal/lysosomal transport of cholesterol, shows a time
dependent decrease of its fluorescence when interacting with
cholesterol molecules [62]. Thus, we further probed the
interaction between human P2 and cholesterol using intrinsic
Trp fluorescence. The binding of cholesterol to P2 was monitored
by observing the protein fluorescence quenching induced by
stoichiometric amounts of ligand. P2, at 9.4 mM, showed a slow
decrease of fluorescence intensity as a function of time, in the
presence of 10 mM cholesterol, that reached a stable value after
120 min at room temperature. The presence of cholesterol,
therefore, involves a decrease of about 25% of fluorescence
intensity of the protein (Figure 6B), which is not detectable when
ethanol alone was added. Since an analogous decrease of human
P2 protein intrinsic fluorescence was observed as was seen for
NPC2 [62,63], we suggest that the binding of cholesterol causes
the quenching of fluorescence from the P2 protein. This
interpretation is well supported by the docking results, showing a
favourable binding of cholesterol into the barrel pocket, with
average distances between Trp aromatic rings and cholesterol
ranging from 7 to 9 A ˚.
Figure 6. Identification of cholesterol as a potential ligand for P2. A. Structure of the more favourable complex of P2 protein with cholesterol
(green), obtained by the docking simulations. The position of the palmitate (orange) found in the crystal is shown for comparison. The polar heads of
the two ligands are coloured by element. The favourable interactions formed at the binding site with Arg106, Arg126, and Tyr128 residues (in sticks)
are shown as black lines. The main hydrophobic contact residues are also shown. Inset: Structure of the more favourable complex of P2 with
palmitate (green), obtained by the docking simulations. The position of the palmitate (blue) as found in the crystal is shown also. Arg106, Arg126, and
Tyr128 and their favourable interactions with the two ligands are shown. B. Emission fluorescence spectra of a) human P2 9.4 mM and b) human P2
9.4 mM plus cholesterol 10 mM after 120 min of incubation at room temperature.
doi:10.1371/journal.pone.0010300.g006
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10300While our experiments indicate cholesterol binding by P2, at the
moment, it is unclear whether the bound cholesterol would
originate from the plasma membrane or from free cholesterol. In
this respect, it is interesting to note that when P2 is purified from
tissue in a lipid-bound form, the major lipid present in the protein
preparation is cholesterol [64]. Since P2 also is localized to
compact myelin, it is likely to bind to the membrane surface at
cholesterol-rich microdomains. In future studies, we aim to
investigate whether P2 is able to bind cholesterol from vesicles,
in experiments analogous to those reported for NPC2 [62,63].
Concluding remarks
We used a recombinant form of human myelin P2 protein to
derive high-resolution structural data on this highly abundant PNS
peripheral membrane protein. The crystal structure allows a better
understanding of potential disease-related epitopes, and provides
clues to the functional mechanisms of P2 in lipid transport and
myelin membrane stabilization. P2 may bind myelin lipids, such as
cholesterol, with high affinity, and it could interact with two
apposing cytoplasmic leaflets of the multilayered myelin mem-
brane simultaneously. P2 may, thus, partially share functions with
MBP, another molecule suggested to act as ‘molecular glue’ in
myelin.
Supporting Information
Figure S1 Purification of recombinant human P2. Top, gel
filtration of purified P2 results in a single peak. Bottom, SDS-
PAGE analysis of the fractions from the gel filtration peak
indicates the expected molecular weight.
Found at: doi:10.1371/journal.pone.0010300.s001 (0.35 MB
DOC)
Figure S2 The N-terminal region of P2. The N terminus is
shown in blue and the C terminus in red. Side chains are shown
for residues 1–10, as well as the N-terminal Met residue. This
region corresponds to the putative membrane-binding peptide
used in the assays.
Found at: doi:10.1371/journal.pone.0010300.s002 (0.43 MB
DOC)
Figure S3 Titration of His-P2 with DPC, followed by intrinsic
Trp fluorescence. The colouring and other details as in Figure 5C,
5D.
Found at: doi:10.1371/journal.pone.0010300.s003 (0.15 MB
DOC)
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